Side-by-side · Research reference

CrystagenvsLiraglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BFDA-ApprovedFlagship14/45 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

01Mechanism of Action

Parameter

Crystagen

Liraglutide

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Liraglutide

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

Once daily, same time each day

Duration

Unknown — chronic administration presumed in animal models

Indefinite for chronic indication

Half-life

Not reported

~13 hrSAXENDA (liraglutide) injectio 2014

Standard dose (T2D, Victoza)

—

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

Standard dose (weight, Saxenda)

—

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

Titration schedule

—

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

Reconstitution

—

Pre-filled commercial pen (no reconstitution)

Timing

—

Any time of day; consistent

04Side Effects & Safety

Parameter

Crystagen

Liraglutide

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

Pancreatitis risk

—

Rare; discontinue if suspected

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

Hypoglycemia

—

Low risk as monotherapy; elevated with sulfonylureas / insulin

Heart rate

—

Modest ↑ resting HR (~2-3 bpm)

Cardiovascular benefit

—

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

05Administration Protocol

Parameter

Crystagen

Liraglutide

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Commercial pre-filled pen, no reconstitution required.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Once daily, same time each day. Take with or without food.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

5. Needle

—

Pen-supplied 32G needle.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Liraglutide

— no documented stacks